Our top pick for
Amyris, Inc is a specialty chemicals business based in the US. Amyris shares (AMRS) are listed on the NASDAQ and all prices are listed in US Dollars. Amyris employs 561 staff and has a trailing 12-month revenue of around USD$134.6 million.
Since the stock market crash in March caused by coronavirus, Amyris's share price has had significant negative movement.
Its last market close was USD$2.32, which is 29.70% down on its pre-crash value of USD$3.3 and 65.71% up on the lowest point reached during the March crash when the shares fell as low as USD$1.4.
If you had bought USD$1,000 worth of Amyris shares at the start of February 2020, those shares would have been worth USD$678.32 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$811.19.
|Latest market close||USD$2.32|
|52-week range||USD$1.4 - USD$6.07|
|50-day moving average||USD$2.9534|
|200-day moving average||USD$3.4717|
|Wall St. target price||USD$10|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.388|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||0.87%|
|1 month (2020-10-30)||-7.20%|
|3 months (2020-08-28)||-31.36%|
|6 months (2020-05-29)||-37.80%|
|1 year (2019-11-29)||-42.29%|
|2 years (2018-11-29)||-51.77%|
|3 years (2017-11-29)||-35.38%|
|5 years (2015-11-27)||48.72%|
|Revenue TTM||USD$134.6 million|
|Gross profit TTM||USD$11.9 million|
|Return on assets TTM||-45.49%|
|Return on equity TTM||0%|
|Market capitalisation||USD$579.1 million|
TTM: trailing 12 months
There are currently 24.5 million Amyris shares held short by investors – that's known as Amyris's "short interest". This figure is 6.1% up from 23.1 million last month.
There are a few different ways that this level of interest in shorting Amyris shares can be evaluated.
Amyris's "short interest ratio" (SIR) is the quantity of Amyris shares currently shorted divided by the average quantity of Amyris shares traded daily (recently around 3.4 million). Amyris's SIR currently stands at 7.13. In other words for every 100,000 Amyris shares traded daily on the market, roughly 7130 shares are currently held short.
However Amyris's short interest can also be evaluated against the total number of Amyris shares, or, against the total number of tradable Amyris shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Amyris's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Amyris shares in existence, roughly 120 shares are currently held short) or 0.2482% of the tradable shares (for every 100,000 tradable Amyris shares, roughly 248 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Amyris.
Find out more about how you can short Amyris stock.
We're not expecting Amyris to pay a dividend over the next 12 months.
Amyris's shares were split on a 1:15 basis on 6 June 2017. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Amyris shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Amyris shares which in turn could have impacted Amyris's share price.
Over the last 12 months, Amyris's shares have ranged in value from as little as $1.4 up to $6.07. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amyris's is 0.5433. This would suggest that Amyris's shares are less volatile than average (for this exchange).
Amyris, Inc., a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.